PPAR gamma (PPARG) Human shRNA Lentiviral Particle (Locus ID 5468)
CAT#: TL320459V
PPARG - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.
Need custom lentivirus service?
Get a free quote
CNY 11,400.00
货期*
详询
规格
Cited in 3 publications. |
经常一起买 (3)
Specifications
Product Data | |
Product Name | PPAR gamma (PPARG) Human shRNA Lentiviral Particle (Locus ID 5468) |
Locus ID | 5468 |
Synonyms | CIMT1; GLM1; NR1C3; PPARG1; PPARG2; PPARG5; PPARgamma |
Vector | pGFP-C-shLenti |
Format | Lentiviral particles |
RefSeq | NM_001330615, NM_005037, NM_015869, NM_138711, NM_138712, NM_001354666, NM_001354667, NM_001354668, NM_001354669, NM_001354670, NM_138712.1, NM_138712.2, NM_138712.3, NM_138711.1, NM_138711.2, NM_138711.3, NM_005037.1, NM_005037.2, NM_005037.3, NM_005037.4, NM_005037.5, NM_015869.1, NM_015869.2, NM_015869.3, NM_015869.4, BC006811, BM923992, NM_138712.4, NM_015869.5, NM_138711.4, NM_005037.6 |
Summary | This gene encodes a member of the peroxisome proliferator-activated receptor (PPAR) subfamily of nuclear receptors. PPARs form heterodimers with retinoid X receptors (RXRs) and these heterodimers regulate transcription of various genes. Three subtypes of PPARs are known: PPAR-alpha, PPAR-delta, and PPAR-gamma. The protein encoded by this gene is PPAR-gamma and is a regulator of adipocyte differentiation. Additionally, PPAR-gamma has been implicated in the pathology of numerous diseases including obesity, diabetes, atherosclerosis and cancer. Alternatively spliced transcript variants that encode different isoforms have been described. [provided by RefSeq, Jul 2008] |
shRNA Design | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service. |
Performance Guaranteed | OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred). |
Citations (3)
The use of this RNAi has been cited in the following citations: |
---|
Epigenetic derepression converts PPARγ into a druggable target in triple-negative and endocrine-resistant breast cancers
,null,
Cell Death Discovery
,PubMed ID 34580286
[PPARG]
|
SetD7 (Set7/9) is a novel target of PPARγ that promotes the adaptive pancreatic β-cell glycemic response
,null,
The Journal of Biological Chemistry
,PubMed ID 34592314
[PPARG]
|
Abscisic acid regulates dormancy of prostate cancer disseminated tumor cells in the bone marrow
,Jung, Y;Cackowski, FC;Yumoto, K;Decker, AM;Wang, Y;Hotchkin, M;Lee, E;Buttitta, L;Taichman, RS;,
Neoplasia (New York, N.Y.) 2021
,PubMed ID 33296752
[PPARG]
|
Documents
Product Manuals |
FAQs |
SDS |
Customer
Reviews
Loading...